Genmab's Phase 3 Rina-S cuts progression risk by 71% in ovarian cancer
Genmab says Rina-S met primary endpoints in a Phase 3 trial in platinum-resistant ovarian cancer. TradingView and GlobeNewswire reported the news.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Genmab reported topline results from its Phase 3 RAINFOL-02 trial. Rina-S met both progression-free survival (PFS) and overall survival (OS) endpoints against chemotherapy in patients with platinum-resistant ovarian cancer.
According to the company, the hazard ratio for PFS was 0.29 in the intention-to-treat population and 0.33 in the primary analysis set (PAS). For OS, the hazard ratios were 0.43 and 0.44 respectively, all with p<0.0001. Safety was consistent with the prior profile, and no new safety signals were identified. Genmab plans to hold regulatory discussions.
The report was published by TradingView and GlobeNewswire, citing Genmab's press release.
why it matters
For markets, the news matters mainly for Genmab shares. A successful Phase 3 readout opens the way to regulatory filings and possible commercialization in gynecologic oncology. Regulatory steps still lie ahead, so the effect on the company's business will depend on submission timing and the regulators' decision.
market impact
Genmab shares: strong Phase 3 data supports expectations for Rina-S approval
tags
instruments
sources
- Genmab A/S (GMAB) Phase 3 Rina-S Cuts PFS Risk 71% in PROC — TradingView, 23 October 2026 at 15:56 UTC
- Genmab A/S (GMAB) Phase 3 Rina-S Cuts PFS Risk 71% in PROC — globenewswire.com, 23 October 2026 at 15:55 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗